Live
- JD-U criticises Pappu Yadav for receiving threatening calls
- INST scientists develop anti-counterfeiting ink to curb document duplication
- 62 dead in flash floods in eastern Spain
- India to face Malaysia in Hyderabad on November 18 for International Friendly
- Militants will get killed as long as they continue to infiltrate: Farooq Abdullah
- PM Modi, HM Shah, CM Yogi among top BJP bigwigs to hold over 170 poll rallies in Maharashtra
- AAP protests against FCI's slow procurement of paddy from Punjab
- Lakshmi Puja 2024: Complete Guide to Diwali Rituals for Prosperity and Good Fortune
- AP govt. appoints BR Naidu as new chairman of TTD
- Odisha CM announces Rs 6 lakh compensation for metro tunnel victims
AP scientist in US makes leadless pacemaker
AP Scientist in US Makes Leadless Pacemaker, The world\'s first leadless pacemaker, developed by an Indian-origin scientist Vivek Reddy, has shown promising results after one year of human trials on 32 patients who received the pacemaker.
- It is a minimally-invasive non-surgical device
- One year of human trials on 32 patients showed promising performance and safety
- It is placed directly inside a patient's heart
Hyderabad: The world's first leadless pacemaker, developed by an Indian-origin scientist Vivek Reddy, has shown promising results after one year of human trials on 32 patients who received the pacemaker.
"This is the first time we have seen one-year follow-up data for this innovative, wireless cardiac pacing technology. Our results show the leadless pacemaker is comparable to traditional pacemakers," said Reddy, director of arrhythmia services at the Mount Sinai Hospital here.
The findings further support the promising performance and safety of this minimally-invasive, non-surgical pacing device. The follow-up study evaluated 32 patients with a slowed heartbeat (bradycardia) who successfully received St. Jude Medical's "Nanostim" leadless pacemaker at two hospitals in Prague and one in Amsterdam. "There was no experience of infections or failure to sense, pace or communicate with the pacemaker," Reddy noted.
The leadless cardiac pacemaker is placed directly inside a patient's heart without surgery during a catheter-guided procedure through the groin via the femoral vein. The device, resembling a tiny, silver tube and smaller than a triple-A battery, is only a few centimetres in length, making it less than 10 per cent the size of a traditional pacemaker.
It works by closely monitoring the heart's electrical rhythms and if the heart beat is too slow it provides electrical stimulation therapy to regulate it. "More long-term follow-up of these 'leadless' study patients will further our understanding of the potential advantages, benefits, and complication risks of leadless pacemaker technology, along with additional ongoing, larger trials," Reddy said.
More than four million patients globally have a pacemaker, and 700,000 new patients receive one each year. Reddy presented the one-year 'leadless' study data findings at 'Heart Rhythm 2014,' the Heart Rhythm Society's 35th annual scientific sessions in San Francisco city in the US May 9.
